NeurogesX has initiated a Phase 1 clinical trial of NGX-1998, a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site.
Filed under: gpcr | Tagged: agonist, Capsaicin, NeurogesX, NGX-1998, NGX1998, TRPV1, Vanilloid | Leave a Comment »
Actelion and GlaxoSmithKline have entered into exclusive collaboration for development of orexin receptor antagonist almorexant. Almorexant is currently in phase III development as a treatment for primary insomnia.
Filed under: Uncategorized | Tagged: ACT-078573, ACT078573, Actelion, almorexant, GlaxoSmithkline, GSK | Leave a Comment »
Mithridion has commenced a Phase I clinical trial of its investigational drug MCD-386 in Alzheimers. MCD-386 appears to activate of muscarinic M1 type receptor subtypes.
Filed under: Uncategorized | Tagged: M1, MCD-386, MCD386, Mithridion, Muscarinic, Muscarinic M1, phase I | Leave a Comment »
